Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 3INTERVENTIONAL

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide. Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Who May Be Eligible (Plain English)

Who May Qualify: - Weight is \>= 20 kg (44 lbs) and \< 135 kg (298 lbs). - History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months. - Participant has to have 4 to 14 migraine days and \< 15 headache days in the 28-day baseline period per eDiary. - To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 \[2018\]) and per investigator judgment is appropriate to receive preventive treatment for migraine. Who Should NOT Join This Trial: - History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018). - Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018). - Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Weight is \>= 20 kg (44 lbs) and \< 135 kg (298 lbs). * History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months. * Participant has to have 4 to 14 migraine days and \< 15 headache days in the 28-day baseline period per eDiary. * To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 \[2018\]) and per investigator judgment is appropriate to receive preventive treatment for migraine. Exclusion Criteria: * History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018). * Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018). * Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).

Treatments Being Tested

DRUG

Atogepant

Oral Tablet

DRUG

Placebo-Matching Atogepant

Oral Tablet

Locations (20)

Rehabilitation & Neurological Services /ID# 248517
Huntsville, Alabama, United States
The Center for Clinical Trials - Saraland /ID# 271604
Saraland, Alabama, United States
Preferred Research Partners /ID# 249729
Little Rock, Arkansas, United States
Preferred Research Partners /ID# 270406
Little Rock, Arkansas, United States
Advanced Research Center /ID# 251381
Anaheim, California, United States
Alliance for Research Alliance for Wellness /ID# 248521
Long Beach, California, United States
Excell Research, Inc /ID# 247532
Oceanside, California, United States
Lumos Clinical Research Center /ID# 249731
San Jose, California, United States
Sunwise Clinical Research /ID# 248529
Walnut Creek, California, United States
Advanced Neurosciences Research, LLC /ID# 247592
Fort Collins, Colorado, United States
Northwest Florida Clinical Research Group, LLC /ID# 251382
Gulf Breeze, Florida, United States
Advanced Research Institute of Miami /ID# 248539
Homestead, Florida, United States
My Preferred Research LLC /ID# 249720
Miami, Florida, United States
Asclepes Research Centers - Spring Hill /ID# 248525
Spring Hill, Florida, United States
Coastal Georgia Child Neurology /ID# 249733
Brunswick, Georgia, United States
Deaconess Clinic - Gateway Health Center /ID# 247589
Newburgh, Indiana, United States
College Park Family Care Center Overland Park /ID# 249734
Overland Park, Kansas, United States
Michigan Headache & Neurological Institute (MHNI) /ID# 247468
Ann Arbor, Michigan, United States
Proven Endpoints LLC /ID# 258066
Ridgeland, Mississippi, United States
Cognitive Clinical Trials (CCT) - Papillion /ID# 248536
Papillion, Nebraska, United States